These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 36557813)

  • 1. AHNAK Contributes to Hepatocellular Carcinoma Growth by Interacting with IGF-1R.
    Li K; Song K; Hou Y; Tian Y; Wang H; Sun L; Li A; Zhang Y
    Molecules; 2022 Dec; 27(24):. PubMed ID: 36557813
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Overexpression of RNF38 facilitates TGF-β signaling by Ubiquitinating and degrading AHNAK in hepatocellular carcinoma.
    Peng R; Zhang PF; Yang X; Wei CY; Huang XY; Cai JB; Lu JC; Gao C; Sun HX; Gao Q; Bai DS; Shi GM; Ke AW; Fan J
    J Exp Clin Cancer Res; 2019 Mar; 38(1):113. PubMed ID: 30836988
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lentivirus-mediated RNAi knockdown of insulin-like growth factor-1 receptor inhibits the growth and invasion of hepatocellular carcinoma via down-regulating midkine expression.
    Bie CQ; Liu XY; Cao MR; Huang QY; Tang HJ; Wang M; Cao GL; Yi TZ; Wu SL; Xu WJ; Tang SH
    Oncotarget; 2016 Nov; 7(48):79305-79318. PubMed ID: 27813495
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Insulin-Like Growth Factor 1 Receptor Drives Hepatocellular Carcinoma Growth and Invasion by Activating Stat3-Midkine-Stat3 Loop.
    Bie C; Chen Y; Tang H; Li Q; Zhong L; Peng X; Shi Y; Lin J; Lai J; Wu S; Tang S
    Dig Dis Sci; 2022 Feb; 67(2):569-584. PubMed ID: 33559791
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CircRNA_0008194 functions as a ceRNA to promote invasion of hepatocellular carcinoma via inhibiting miR-190a/AHNAK signaling pathway.
    Liu W; Pan Y; Zhu H; Zhou Y; Zhang H; Liu L; Liu Q; Ji G
    J Clin Lab Anal; 2022 Apr; 36(4):e24286. PubMed ID: 35199873
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long non-coding RNA deleted in lymphocytic leukaemia 1 promotes hepatocellular carcinoma progression by sponging miR-133a to regulate IGF-1R expression.
    Zhang W; Liu S; Liu K; Liu Y
    J Cell Mol Med; 2019 Aug; 23(8):5154-5164. PubMed ID: 31207081
    [TBL] [Abstract][Full Text] [Related]  

  • 7. EGCG inhibits activation of the insulin-like growth factor (IGF)/IGF-1 receptor axis in human hepatocellular carcinoma cells.
    Shimizu M; Shirakami Y; Sakai H; Tatebe H; Nakagawa T; Hara Y; Weinstein IB; Moriwaki H
    Cancer Lett; 2008 Apr; 262(1):10-8. PubMed ID: 18164805
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Epithelial-mesenchymal transition predicts sensitivity to the dual IGF-1R/IR inhibitor OSI-906 in hepatocellular carcinoma cell lines.
    Zhao H; Desai V; Wang J; Epstein DM; Miglarese M; Buck E
    Mol Cancer Ther; 2012 Feb; 11(2):503-13. PubMed ID: 22161861
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MiR-505 suppressed the growth of hepatocellular carcinoma cells via targeting IGF-1R.
    Ren L; Yao Y; Wang Y; Wang S
    Biosci Rep; 2019 Jul; 39(7):. PubMed ID: 31160483
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Insulin-like growth factor-1 receptor inhibition induces a resistance mechanism via the epidermal growth factor receptor/HER3/AKT signaling pathway: rational basis for cotargeting insulin-like growth factor-1 receptor and epidermal growth factor receptor in hepatocellular carcinoma.
    Desbois-Mouthon C; Baron A; Blivet-Van Eggelpoël MJ; Fartoux L; Venot C; Bladt F; Housset C; Rosmorduc O
    Clin Cancer Res; 2009 Sep; 15(17):5445-56. PubMed ID: 19706799
    [TBL] [Abstract][Full Text] [Related]  

  • 11. miR-455-5p suppresses hepatocellular carcinoma cell growth and invasion via IGF-1R/AKT/GLUT1 pathway by targeting IGF-1R.
    Hu Y; Yang Z; Bao D; Ni JS; Lou J
    Pathol Res Pract; 2019 Dec; 215(12):152674. PubMed ID: 31732382
    [TBL] [Abstract][Full Text] [Related]  

  • 12. IGF activation in a molecular subclass of hepatocellular carcinoma and pre-clinical efficacy of IGF-1R blockage.
    Tovar V; Alsinet C; Villanueva A; Hoshida Y; Chiang DY; Solé M; Thung S; Moyano S; Toffanin S; Mínguez B; Cabellos L; Peix J; Schwartz M; Mazzaferro V; Bruix J; Llovet JM
    J Hepatol; 2010 Apr; 52(4):550-9. PubMed ID: 20206398
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MiR-448 suppresses cell proliferation and glycolysis of hepatocellular carcinoma through inhibiting IGF-1R expression.
    Wang Y; Chen X; Yao N; Gong J; Cao Y; Su X; Feng X; Tao M
    J Gastrointest Oncol; 2022 Feb; 13(1):355-367. PubMed ID: 35284123
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vivo CRISPR screen identifies LTN1 as a novel tumor suppressor ubiquitinating insulin-like growth factor 2 mRNA-binding protein 1 in hepatocellular carcinoma.
    Peng R; Cao J; Zhang C; Zhou J; Su BB; Tu DY; Jiang GQ; Jin SJ; Xu YP; Bai DS
    Hepatol Commun; 2023 Oct; 7(10):. PubMed ID: 37708447
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nogo-C contributes to HCC tumorigenesis via suppressing cell growth and its interactome analysis with comparative proteomics research.
    Liu X; Cui SJ; Zhu SJ; Geng DC; Yu L
    Int J Clin Exp Pathol; 2014; 7(5):2044-55. PubMed ID: 24966913
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of IGF-1R/EGFR cross-talks on hepatoma cell sensitivity to gefitinib.
    Desbois-Mouthon C; Cacheux W; Blivet-Van Eggelpoël MJ; Barbu V; Fartoux L; Poupon R; Housset C; Rosmorduc O
    Int J Cancer; 2006 Dec; 119(11):2557-66. PubMed ID: 16988945
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MicroRNA-133a functions as a tumor suppressor by targeting IGF-1R in hepatocellular carcinoma.
    Zhang W; Liu K; Liu S; Ji B; Wang Y; Liu Y
    Tumour Biol; 2015 Dec; 36(12):9779-88. PubMed ID: 26156803
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Increased expression of insulin-like growth factor-1 receptor predicts poor prognosis in patients with hepatocellular carcinoma.
    Zhang Z; Lei B; Chai W; Liu R; Li T
    Medicine (Baltimore); 2019 Nov; 98(44):e17680. PubMed ID: 31689787
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MiR-503 inhibits hepatocellular carcinoma cell growth via inhibition of insulin-like growth factor 1 receptor.
    Xiao Y; Tian Q; He J; Huang M; Yang C; Gong L
    Onco Targets Ther; 2016; 9():3535-44. PubMed ID: 27366090
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A pleiotropic effect of the single clustered hepatic metastamiRs miR-96-5p and miR-182-5p on insulin-like growth factor II, insulin-like growth factor-1 receptor and insulin-like growth factor-binding protein-3 in hepatocellular carcinoma.
    Assal RA; El Tayebi HM; Hosny KA; Esmat G; Abdelaziz AI
    Mol Med Rep; 2015 Jul; 12(1):645-50. PubMed ID: 25739014
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.